This guideline intends to provide general guidance, at the current moment, related to the necessity, role, establishment, and management of a data monitoring committee (DMC) in a clinical study (trial) of a drug or medical device (hereafter referred to as “drug, etc.”) by a sponsor (including those who conduct clinical trials by themselves).